Nasdaq:US$16.81 (+0.49) | HKEX:HK$27.25 (+0.85) | AIM:£2.56 (+0.11)
搜索
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2013-04-06

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer